Gastrointestinal (GI) randomized event and safety open-label NSAID [nonsteroidal anti-inflammatory] study (GI-Reasons): A randomised, open-label, blinded-endpoint, parallel-group trial of GI safety of celecoxib compared with non-selective nonsteroidal antiinflammatory drugs (NSAIDs) in osteoarthritis patients.

Trial Profile

Gastrointestinal (GI) randomized event and safety open-label NSAID [nonsteroidal anti-inflammatory] study (GI-Reasons): A randomised, open-label, blinded-endpoint, parallel-group trial of GI safety of celecoxib compared with non-selective nonsteroidal antiinflammatory drugs (NSAIDs) in osteoarthritis patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Celecoxib; Diclofenac; Meloxicam; Nabumetone; Naproxen; Nonsteroidal anti-inflammatories
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Acronyms GI-Reasons
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 02 Nov 2011 Results presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.
    • 26 Oct 2011 Actual end date changed from May 2010 to November 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top